Explore more publications!
Tech Channel Madagascar
Got News to Share?

Tech Channel Madagascar: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Channel Madagascar.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 8, 2025

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
December 8, 2025

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs

Indeterminate GlobeNewswire
Rocket Doctor AI, Health Cities and CAN Health Network Partner to Advance AI-Powered Clinical Decision Support in Alberta
December 8, 2025

Rocket Doctor AI, Health Cities and CAN Health Network Partner to Advance AI-Powered Clinical Decision Support in Alberta

Indeterminate GlobeNewswire
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
December 8, 2025

Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies

Indeterminate GlobeNewswire
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees
December 8, 2025

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees

Indeterminate GlobeNewswire
Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy
December 8, 2025

Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy

Indeterminate GlobeNewswire
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
December 8, 2025

Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa

Indeterminate GlobeNewswire
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
December 8, 2025

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Indeterminate GlobeNewswire
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
December 8, 2025

BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review

Indeterminate GlobeNewswire
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
December 8, 2025

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

Indeterminate GlobeNewswire
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 8, 2025

Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Indeterminate GlobeNewswire
1 billion financing empowers! EngineAI T800 comes out in a big way, accelerating industrialization process
December 8, 2025

1 billion financing empowers! EngineAI T800 comes out in a big way, accelerating industrialization process

Indeterminate GlobeNewswire
REKT Announces Launch of the First Meme Token That Rewards Losing Trades
December 8, 2025

REKT Announces Launch of the First Meme Token That Rewards Losing Trades

Indeterminate GlobeNewswire
Kraig Biocraft Laboratories Secures Usage Rights to Strategic Government-Owned Mulberry Gardens to Support Major Spider Silk Production Expansion
December 8, 2025

Kraig Biocraft Laboratories Secures Usage Rights to Strategic Government-Owned Mulberry Gardens to Support Major Spider Silk Production Expansion

Indeterminate GlobeNewswire
Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment
December 8, 2025

Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment

Indeterminate GlobeNewswire
The Acceleration Continues: Vetty Named One of Nucleus Research’s Hot Companies to Watch in 2026
December 8, 2025

The Acceleration Continues: Vetty Named One of Nucleus Research’s Hot Companies to Watch in 2026

Indeterminate GlobeNewswire
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting
December 8, 2025

Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting

Indeterminate GlobeNewswire
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis
December 8, 2025

Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis

Indeterminate GlobeNewswire
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
December 8, 2025

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Indeterminate GlobeNewswire
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference
December 8, 2025

Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference

Indeterminate GlobeNewswire
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD
December 8, 2025

Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions